1Dodd RY.Adverse consequences of blood transfusion:Quantitative risk estimates.In:Blood Supply:Risks Perceptions,and Prospects for the Future[M].Nance ST (ED).Bethesda:American Association of Blood Banks,1994.1-24.
2Goodnough LT,Brecher ME,Kanter MH,et al.Transfusion medicine.First of two parts-blood transfusion[J].New Engl J Med,1999,340(6):438-447.
3Selik RM,Ward JW,Buehler JW.Trends in transfusion-associated acquired immune deficiency syndrome in the United States:1982 through 1991[J].Transfusion,1993,33(11):890-893.
4Cookson ST,Arduino MJ,Aguero SM,et al.Yersinia study group: Yersinia entercollitica-contaminatied red blood cells-An emerging threat to blood safety[M].In: Program and abstracts of the 36 th Interscience Conference on Antimicrobial Agents and Chemotherapy.Washington D.C.: American Society for Microbiology,1996.237
5Ness PM,Braine HG,King K, et al.Single-donor platelets reduce the risk of septic platelet transfusion reactions[J].Transfusion,2001,41(7):857-861.
2Bruisten SM,Oudshoorn P,van Swieten P,et al. Stability of HIV-1 RNA in blood during specimen handing and storage prior to amplification by NASBA-QT. J Virol Meth, 1997,67:199.
3Schreiber GB, Bush MP, Kleinman SH, et al. The risk of transfusion-transmitted viral infection. The Retrovirus Epidemiology Donors Study. N Engl J Med, 1996,334:1685.
4Gallarda JL,Dragon E. Blood screening by nucleic acid amplification technology: current issues, furore challenges. Mol Diag,2000,5:11.
5Noeel, L. GAT testing:added value. In:Smit Sibinga C Th, Alters HJ,eds. Risk management in blood transfusion:The virtue of reality. Dordrecht, Kluwer Academic Publishers, 1999:109-117.
6Murthy KK,Henrard DR,Eichberg JW,et al. Redifining the HIV-infectious window period in chimpanzee model: Evidence to suggest that viral nucleic acld testing can prevent blood-home transmission. Transfusion, 1999,39: 688.
